Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Amplia Therapeutics has entered into a preclinical collaboration with Korean drug screening company Next&Bio to study the effects of its FAK inhibitors in combination with kRas inhibitors for treating pancreatic cancer. This partnership aims to explore new commercial opportunities by testing these compounds on patient-derived cancer cells. Amplia’s strategic move could potentially enhance the development of targeted therapies in the fight against cancer.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
